Clinical Trial Update: A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer [Phase 1]

View source ↗

Summary

This Phase 1 trial assesses BI 765179 alone and with Ezabenlimab in advanced solid tumors, and BI 765179 with Pembrolizumab in advanced head and neck cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Solid Tumors

Drugs mentioned

• BI 765179
• Pembrolizumab (pembrolizumab)
• ezabenlimab (ezabenlimab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Neoplasms | Phase 1 | Status: ACTIVE_NOT_RECRUITING